key: cord-0760156-geu5t5u4
authors: Vyavahare, Sagar; Kumar, Sandeep; Cantu, Nicholas; Kolhe, Ravindra; Bollag, Wendy B.; McGee-Lawrence, Meghan E.; Hill, William D.; Hamrick, Mark W.; Isales, Carlos M.; Fulzele, Sadanand
title: Tryptophan-Kynurenine Pathway in COVID-19-Dependent Musculoskeletal Pathology: A Minireview
date: 2021-10-05
journal: Mediators Inflamm
DOI: 10.1155/2021/2911578
sha: b548a2ffefbf8b883b9c76b0191aedc1a8c1d5a6
doc_id: 760156
cord_uid: geu5t5u4

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19), affecting multiple organ systems, including the respiratory tract and lungs. Several studies have reported that the tryptophan-kynurenine pathway is altered in COVID-19 patients. The tryptophan-kynurenine pathway plays a vital role in regulating inflammation, metabolism, immune responses, and musculoskeletal system biology. In this minireview, we surmise the effects of the kynurenine pathway in COVID-19 patients and how this pathway might impact muscle and bone biology.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the current pandemic, suspected to originate from infected bats [1] . Coronavirus disease 2019 , caused by SARS-CoV-2, has turned out to be a major global catastrophe affecting millions of individuals across the globe [2] . In the United States, as of today, more than 30 million lives have been affected by COVID-19, and over six hundred thousand Americans have lost their lives, according to the Johns Hopkins Coronavirus Resource Center [3] . COVID-19 can present a wide spectrum of symptoms such as cough, fever, shortness of breath, muscle pain, and loss of taste and smell [4] . Mild to severely affected patients may experience elevated proinflammatory cytokines such as IL-1, TNF-α, and IL-6 [5] , which negatively affect human health (Figure 1 ). Excessive activation of these proin-flammatory cytokines (cytokine storm) leads to the alteration of several metabolic signaling pathways (e.g., the tryptophan-kynurenine pathway).

Recent studies have shown that the tryptophankynurenine pathway (Trp-Kyn) is altered in COVID-19 patients. A study conducted by Thomas et al. analyzed serum metabolites of COVID-19 patients and found that tryptophan (Trp) levels were reduced, and L-kynurenine (Kyn) was elevated [5] . A study performed by Fraser et al. reported similar findings (elevated levels of Kyn in COVID-19 patients) [6] . Another study reported that Kyn levels were elevated, along with kynurenic acid (Kyn-A) and quinolinic acid (QA) in the serum of COVID-19 patients [7] . The study conducted by Lawler et al. demonstrated elevated levels of QA in the blood plasma of COVID-19 patients [8] . Sex-specific differences have also been reported in the levels of Kyn-A and QA metabolites in COVID-19 patients. Serum metabolic analyses performed by Cai et al. reported elevated levels of Kyn-A in male patients compared to female patients [9] . Lionetto et al. assessed serum metabolites in COVID-19 patients and found that Kyn/Trp levels were elevated in male patients [10] . Moreover, Cai et al. (2020) reported an elevated Kyn-A: L-Kyn was associated with increased severity of COVID-19 infection in male patients [9] . The studies mentioned above indicate that activation of the tryptophankynurenine pathway might be one of the reasons for the increased susceptibility of males to COVID-19 infection.

Several studies also reported elevated levels of genes involved in tryptophan metabolic pathways [11, 12] . The study conducted by Policard et al. reported that indoleamine-pyrrole 2,3-dioxygenase (IDO-1) is significantly upregulated in COVID-19 patients [11] . Another study also reported similar findings showing elevated levels of IDO-1 in COVID-19 patients [12] . The study conducted by Grunewald et al. in the murine model demonstrated that IDO-1, IDO-2, and TDO-2 were significantly upregulated in murine coronavirus infection [13] . The prevalence and severity of COVID-19 disease are directly associated with age and the underlying condition, such as diabetes, obesity, and cardiovascular disorders [14, 15] . It is well known that the tryptophan-kynurenine pathway elevated with age and above mentioned underlying conditions [16] .

The findings from these studies strongly indicate that the Trp-Kyn pathway is altered in COVID-19 patients, leading to a decrease in Trp levels and an increase in Kyn and its metabolites. Recent studies also demonstrated reduced muscle mass and bone loss in COVID-19 patients [17] [18] [19] [20] . Based on the findings from our group and published literature, we came up with a novel perspective suggesting that the activation of the Trp-Kyn pathway in COVID-19 patients might be involved in bone and muscle loss.

Tryptophan (Trp) is an essential amino acid that plays a vital role in protein synthesis, growth, mental health, and immune responses [21] . As age advances, proinflammatory cytokines, such as IL-6, IL-1β, and IFN-γ, lead to the activation of indoleamine 2,3-dioxygenase (IDO-1) [22] . An increase in levels/activity of IDO-1 along with inflammaging further leads to immunosuppression, neurodegenerative disorders, cardiovascular diseases, and fragility [21] [22] [23] [24] . Augmentation of the levels/activity of IDO-1 decreases Trp levels and leads to the generation of several Trp intermediate metabolites [25] . Trp is catabolized by rate-limiting enzymes such as indoleamine 2,3-dioxygenase-1 (IDO-1), indoleamine 2,3-dioxygenase-2 (IDO-2), and tryptophan 2,3-dioxygenase-2 (TDO-2) into N-formylkynurenine and Kyn [26] . Further, Kyn is broken down into Kyn-A and 3hydroxykynurenine by kynurenine aminotransferases (KAT) and kynurenine 3-monooxygenase (KMO) [27] . Trp also acts as a substrate for the generation of nicotinamide adenine dinucleotide (NAD+) through the conversion of quinolinic acid. NAD+ plays a crucial role in regulating several cellular processes, including energy production, chromosome stability, immune cell signaling, longevity mechanisms, and DNA repair [28, 29] . The Kyn and its metabolites induce downstream signaling by directly activating Ahr signaling [30] and/or indirect activation of the MEK-(mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) kinase-) ERK1/2 MAPK signaling pathway [31, 32] . IDO-1 is a master regulator of the Kyn pathway and downstream regulator of interferon signaling [33] , which is activated during viral infection [34] . On the other hand, it has been reported that interferon-γ stimulates the expression of ACE2 (the receptor for SARS-CoV-2) in COVID-19 infection [35] . Hence, the interferon-γ signaling cascade Mediators of Inflammation potentiates inflammation in SARS-CoV-2 pathology [5] . Enhanced inflammation further leads to an increase in IDO-1 activity followed by enhanced degradation of Trp into Kyn and its metabolites. Our group identified the Trp-Kyn catabolic pathway as a novel causal mechanism in age-associated musculoskeletal complications (stem cell dysfunction and muscle and bone loss). We hypothesized that elevated levels of Kyn and its metabolites might be involved in COVID-19 musculoskeletal pathophysiology ( Figure 2 ).

Kyn is known to increase with age and is involved in deleterious effects on the musculoskeletal system [24, [36] [37] [38] .

Recently published data have demonstrated a loss of bone and muscle in COVID-19 patients [17] [18] [19] [20] . We hypothesize that an increase in cytokine levels leads to activation of the IDO-Kyn pathway, which raises the levels of Kyn and its metabolites, leading to activation of the aryl hydrocarbon receptor (AhR) and downstream signaling. Induction of AhR signaling directly by viral particles [39] or by Kyn metabolites leads to bone and muscle loss. Viral infection activates AhR through an IDO1-AhR-IDO1-positive feedback loop, which eventually causes upregulation of downstream effectors, such as TCDD-inducible PARP (TiPARP), and enhances the expression of cytokines (e.g., interleukin IL-1β, IL-10, and TNF-α) [39] . Therefore, we hypothesize that elevations in the cytokine expression elicit IDO-Kyn-AhR activation that results in bone and muscle loss.

There is conclusive evidence demonstrating that Kyn increases bone resorption by activating the AhR signaling pathway [38, 40, 41 ]. An increase in Kyn levels accelerates skeletal aging, leading to decreased osteoblast numbers and increased osteoclast numbers and activity, resulting in bone loss via decreased formation and enhanced resorption [42] . The study performed by our group analyzed the direct effects of feeding Kyn on bone mass and also evaluated the short-term effects of intraperitoneal injection of Kyn on bone turnover in CD-1 mice [24] . Micro-CT analysis revealed a significant bone loss upon Kyn feeding in adult mice, and serum analysis revealed an increase in the levels of osteoclastogenic markers such as RANKL and pyridinoline crosslinks (PYD) [24] . Our study also reported an increase in bone marrow adiposity with Kyn treatment. Moreover, bone marrow stromal cells isolated from Kyninjected mice showed a decrease in the expression of Hdac-3 and its cofactor NcoR1 and augmentation of the expression of lipid storage genes such as Cidec and Plin1 [24] , suggesting a phenotype similar to accelerated aging since such changes are also observed in aged bone marrow cells [43] . A study conducted by Kalaska et al. revealed that elevated Kyn levels decrease bone strength in rats [44] . Kyn metabolites may also exert effects on bone: a study performed by Darlington et al. measured the ratio of 3-hydroxyanthranilic acid to anthranilic acid and found that anthranilic acid levels were increased, and 3-hydroxyanthranilic acid levels were decreased in osteoporotic patients [45] .

Studies performed by our group have shown that in vitro treatment of RAW264.7 cells, a macrophage-like cells line, 3 Mediators of Inflammation with Kyn induces osteoclastogenesis by upregulating osteoclast transcription factors (such as c-fos and NFATc1) which leads to an increase in TRAP+ osteoclasts [40] . Another metabolite, Kyn-A, inhibits the differentiation of osteoblasts and increases osteoclastogenesis through the extracellular signal-regulated kinase (ERK) pathway [36, 46] . Another study conducted by our group demonstrated that Kyn treatment of human and mouse myoblasts increases reactive oxygen species formation [47] . Consistent with this in vitro studies, in vivo treatment of mice with Kyn leads to increased lipid peroxidation accompanied by reduced muscle size and muscle strength [47] . Several Trp downstream metabolites such as Kyn, Kyn-A, and 3-hydroxykynurenine are endogenous AhR ligands likely to induce musculoskeletal damage [38, 40, 41, 48] .

The decline in tryptophan levels and elevated levels of Kyn and its metabolites postcovid will affect not only musculoskeletal health but also accelerate other age-related diseases (such as Alzheimer and Parkinson). The decline in tryptophan levels will impair the serotonin and melatonin pathway, which leads to the development of neurological disorders such as depression, cognitive impairment, sleep disorder, Alzheimer, and Parkinson's [49] . Moreover, a decrease in tryptophan levels will also affect protein synthesis leading to weight loss and muscular atrophy [50] . Some of the comorbidities that have been associated with severe COVID-19 are aging, diabetes, hypertension, chronic lung disease, cancer, and HIV. It is well known that the tryptophan-Kyn pathway is activated in the abovementioned conditions [51] [52] [53] [54] [55] .

Inhibiting Trp-Kyn and/or AhR signaling may represent a novel therapeutic approach for preventing COVID-19dependent musculoskeletal health and other age-related diseases. There are several Trp-Kyn/Ahr inhibitors that are undergoing clinical trials for various diseased conditions [56] . Currently, indoximod (IDO inhibitor), epacadostat (IDO inhibitor), and IK175 (Ahr inhibitor) are being used for inhibiting Trp-Kyn-Ahr signaling [26] .

Current studies regarding the activation of the IDO-Kyn-AhR pathway in COVID-19 patients have opened up a new frontier for the scientific research community. Based on the available literature, it seems inevitable that activation of the IDO-Kyn-AhR pathway in COVID-19 patients should lead to bone and muscle loss, inducing significant musculoskeletal damage. However, there is currently advancement in COVID-19 therapies (Figure 3 ), but no strategies are available to address musculoskeletal-related issues. Given that the IDO-Kyn-AhR pathway is activated in COVID-19 patients, the use of inhibitors of IDO and/or AhR might be beneficial to reduce or prevent bone and muscle loss in this disease. IDO1 inhibitors (such as indoximod) and AhR inhibitors (e.g., IK 175) may help prevent bone and muscle loss. Some of these inhibitors are currently in clinical trials to treat several cancers and related complications. However, we suggest the necessity of conducting detailed clinical studies to design therapeutic strategies using these inhibitors to prevent bone and muscle loss in COVID-19 patients. The above-discussed literature is based on old variants of COVID-19. It will be interesting to know how delta and other recent variants circulating in the population will affect the IDO-Kyn-AhR pathway.

The data supporting this review are from previously reported studies and datasets, which have been cited.

The authors also declare that there is no other conflict of interest regarding the publication of this manuscript. The abovementioned funding did not lead to any conflict of interest regarding the publication of this manuscript. 

SARS-CoV-2 in animals: potential for unknown reservoir hosts and public health implications

Chloroquine and Hydroxychloroquine for the prevention and treatment of COVID-19: a fiction, Hope or hype? An updated review

An interactive web-based dashboard to track COVID-19 in real time

Neurologic manifestations of hospitalized patients with coronavirus disease

COVID-19 infection alters kynurenine and fatty acid metabolism, correlating with IL-6 levels and renal status

Metabolomics profiling of critically ill coronavirus disease 2019 patients: identification of diagnostic and prognostic biomarkers

Proteomic and metabolomic characterization of COVID-19 patient sera

Systemic perturbations in amine and kynurenine metabolism associated with acute SARS-CoV-2 infection and inflammatory cytokine responses

Kynurenic acid underlies sex-specific immune responses to COVID-19

Increased kynurenineto-tryptophan ratio in the serum of patients infected with SARS-CoV2: An observational cohort study

Immune characterization and profiles of SARS-CoV-2 infected patients reveals potential host therapeutic targets and SARS-CoV-2 oncogenesis mechanism

SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes

Murine coronavirus infection activates the aryl hydrocarbon receptor in an indoleamine 2,3-dioxygenaseindependent manner, contributing to cytokine modulation and proviral TCDD-inducible-PARP expression

Interrelations between COVID-19 and other disorders

Coronavirus disease 2019 hospitalizations attributable to cardiometabolic conditions in the United States: a comparative risk assessment analysis

Insulin resistance and dysregulation of tryptophan-kynurenine and kynurenine-nicotinamide adenine dinucleotide metabolic pathways

Osteoporosis care amidst the prolonged pandemic

Musculoskeletal involvement of COVID-19: review of imaging

Reduced muscle mass as predictor of intensive care unit hospitalization in COVID-19 patients

Dreadful Consequences of Sarcopenia and Osteoporosis Due to COVID-19 Containment

Tryptophan biochemistry: structural, nutritional, metabolic, and medical aspects in humans

Alterations of multiple peripheral inflammatory cytokine levels after repeated ketamine infusions in major depressive disorder

Recent evidence for an expanded role of the kynurenine pathway of tryptophan metabolism in neurological diseases

Kynurenine, a tryptophan metabolite that accumulates with age, induces bone loss

Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond

Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors in clinical trials for cancer immunotherapy

Dysregulation of kynurenine metabolism is related to proinflammatory cytokines, attention, and prefrontal cortex volume in schizophrenia

NAD+/NADH and NADP+/NADPH in cellular functions and cell death: regulation and biological consequences

Role of nicotinamide in genomic stability and skin cancer chemoprevention

Functional role of kynurenine and aryl hydrocarbon receptor axis in chronic rhinosinusitis with nasal polyps

Kynurenine increases matrix metalloproteinase-1 and -3 expression in cultured dermal fibroblasts and improves scarring _in vivo

Mitogen-activated protein kinase/extracellular signal-regulated kinase attenuates 3-hydroxykynurenine-induced neuronal cell death

Trisomy 21 activates the kynurenine pathway via increased dosage of interferon receptors

Critical role for STAT4 activation by type 1 interferons in the interferon gamma response to viral infection

Interferons and viruses induce a novel truncated ACE2 isoform and not the full-length SARS-CoV-2 receptor

Regulation of the maturation of osteoblasts and osteoclastogenesis by glutamate

The kynurenine connection: how exercise shifts muscle tryptophan metabolism and affects energy homeostasis, the immune system, and the brain

Kynurenine inhibits autophagy and promotes senescence in aged bone marrow mesenchymal stem cells through the aryl hydrocarbon receptor pathway

AhR and IDO1 in pathogenesis of Covid-19 and the "systemic AhR activation syndrome:" a translational review and therapeutic perspectives

Kynurenine promotes RANKL-induced osteoclastogenesis in vitro by activating the aryl hydrocarbon receptor pathway

Involvement of aryl hydrocarbon receptor in L-kynurenine-mediated parathyroid hormone-related peptide expression

The detrimental effects of kynurenine, a tryptophan metabolite, on human bone metabolism

Hdac3 deficiency increases marrow adiposity and induces lipid storage and glucocorticoid metabolism in osteochondroprogenitor cells

Elevated levels of peripheral kynurenine decrease bone strength in rats with chronic kidney disease

On the biological importance of the 3-hydroxyanthranilic acid: anthranilic acid ratio

An expanding range of targets for kynurenine metabolites of tryptophan

Kynurenine, a Tryptophan Metabolite That Increases with Age, Induces Muscle Atrophy and Lipid Peroxidation

The multiple faces of tryptophan in bone biology

L-tryptophan: basic metabolic functions, behavioral research and therapeutic indications

Low levels of serum tryptophan underlie skeletal muscle atrophy

Tryptophan, kynurenine pathway, and diabetic ketoacidosis in type 1 diabetes

Tryptophan metabolic pathways are altered in obesity and are associated with systemic inflammation

Dysregulation of the tryptophan pathway evidences gender differences in COPD

Kynurenines as a novel target for the treatment of malignancies

Tryptophan metabolism activates aryl hydrocarbon receptor-mediated pathway to promote HIV-1 infection and reactivation

The therapeutic potential of targeting tryptophan catabolism in cancer